Omega Therapeutics Statistics
Share Statistics
Omega Therapeutics has 55.37M shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 55.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.20M |
| Failed to Deliver (FTD) Shares | 310 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 6.36M, so 11.49% of the outstanding shares have been sold short.
| Short Interest | 6.36M |
| Short % of Shares Out | 11.49% |
| Short % of Float | 33.15% |
| Short Ratio (days to cover) | 16.34 |
Valuation Ratios
The PE ratio is -1.67 and the forward PE ratio is -1.25.
| PE Ratio | -1.67 |
| Forward PE | -1.25 |
| PS Ratio | 52.54 |
| Forward PS | 14.1 |
| PB Ratio | 2.8 |
| P/FCF Ratio | -1.72 |
| PEG Ratio | n/a |
Enterprise Valuation
Omega Therapeutics Inc. has an Enterprise Value (EV) of 222.56M.
| EV / Earnings | -2.28 |
| EV / Sales | 71.93 |
| EV / EBITDA | -2.38 |
| EV / EBIT | -2.22 |
| EV / FCF | -2.36 |
Financial Position
The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.52.
| Current Ratio | 3.35 |
| Quick Ratio | 3.35 |
| Debt / Equity | 0.52 |
| Total Debt / Capitalization | 34.22 |
| Cash Flow / Debt | -3.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.68% and return on capital (ROIC) is -53.78%.
| Return on Equity (ROE) | -1.68% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -53.78% |
| Revenue Per Employee | 33.27K |
| Profits Per Employee | -1.05M |
| Employee Count | 93 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -59.92% in the last 52 weeks. The beta is 1.84, so Omega Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.84 |
| 52-Week Price Change | -59.92% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 50.75 |
| Average Volume (20 Days) | 308.05K |
Income Statement
In the last 12 months, Omega Therapeutics had revenue of $3.09M and earned -$97.43M in profits. Earnings per share was $-1.8.
| Revenue | 3.09M |
| Gross Profit | -62.77M |
| Operating Income | -100.26M |
| Net Income | -97.43M |
| EBITDA | -93.49M |
| EBIT | -100.26M |
| Earnings Per Share (EPS) | -1.8 |
Balance Sheet
The company has $68.44M in cash and $128.43M in debt, giving a net cash position of -$59.98M.
| Cash & Cash Equivalents | 68.44M |
| Total Debt | 128.43M |
| Net Cash | -59.98M |
| Retained Earnings | -334.63M |
| Total Assets | 152.73M |
| Working Capital | 14.78M |
Cash Flow
In the last 12 months, operating cash flow was -$91.51M and capital expenditures -$2.87M, giving a free cash flow of -$94.38M.
| Operating Cash Flow | -91.51M |
| Capital Expenditures | -2.87M |
| Free Cash Flow | -94.38M |
| FCF Per Share | -1.75 |
Margins
Gross margin is -2.03K%, with operating and profit margins of -3.24K% and -3.15K%.
| Gross Margin | -2.03K% |
| Operating Margin | -3.24K% |
| Pretax Margin | -3.15K% |
| Profit Margin | -3.15K% |
| EBITDA Margin | -3.02K% |
| EBIT Margin | -3.24K% |
| FCF Margin | -3.05K% |
Dividends & Yields
OMGA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -181.82% |
| FCF Yield | -173.01% |
Analyst Forecast
The average price target for OMGA is $12, which is 1112.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 1112.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -4.74 |
| Piotroski F-Score | 4 |